What’s new in psoriasis? Analysis of the clinical significance of new guidelines and systematic reviews on psoriasis published in 2008 and 2009
暂无分享,去创建一个
[1] Justin Bailey,et al. Topical treatments for chronic plaque psoriasis. , 2010, American family physician.
[2] J. Gelfand,et al. Complementary and alternative medicine for psoriasis: a qualitative review of the clinical trial literature. , 2009, Journal of the American Academy of Dermatology.
[3] S. Papanicolaou,et al. PSY12 ECONOMIC AND CLINICAL EFFICACY BENEFITS OF THE USE OF USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GREECE , 2009 .
[4] L. Naldi,et al. European S3‐Guidelines on the systemic treatment of psoriasis vulgaris , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.
[5] R. Balkrishnan,et al. Using ‘number needed to treat’ to help conceptualize the magnitude of benefit and risk of tumour necrosis factor‐α inhibitors for patients with severe psoriasis , 2009, The British journal of dermatology.
[6] Courtney I. Jarvis,et al. Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis , 2009, The Annals of pharmacotherapy.
[7] P. Sfikakis,et al. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. , 2009, Journal of the American Academy of Dermatology.
[8] A. Gottlieb,et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. , 2009, Journal of the American Academy of Dermatology.
[9] M. Falagas,et al. The therapeutic effect of balneotherapy: evaluation of the evidence from randomised controlled trials , 2009, International journal of clinical practice.
[10] J. Schmitt,et al. Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress Targeted Treatment of Psoriasis with Adalimumab: a Critical Appraisal Based on a Systematic Review of the Literature , 2022 .
[11] M. Lebwohl,et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. , 2009, Journal of the American Academy of Dermatology.
[12] E. Loveman,et al. Infliximab for the treatment of adults with psoriasis. , 2009, Health Technology Assessment.
[13] G. Fiorino,et al. Review article: anti TNF‐α induced psoriasis in patients with inflammatory bowel disease , 2009, Alimentary pharmacology & therapeutics.
[14] A. Gottlieb,et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. , 2009, Journal of the American Academy of Dermatology.
[15] S. Prey,et al. Effect of folic or folinic acid supplementation on methotrexate‐associated safety and efficacy in inflammatory disease: a systematic review , 2009, The British journal of dermatology.
[16] A. Gottlieb,et al. Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases , 2009, The Journal of dermatological treatment.
[17] M. Lebwohl,et al. Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation. , 2009, Journal of the American Academy of Dermatology.
[18] R. Willemsen,et al. Alexithymia and dermatology: the state of the art , 2008, International journal of dermatology.
[19] J. S. Henning,et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. , 2008, Arthritis and rheumatism.
[20] C. Griffiths,et al. Pathogenesis and clinical features of psoriasis , 2007, The Lancet.